| CAPRICOR THERAPEUTICS |
| USA |
| Gesundheit |
| US14070B3096 / A2PLU4 |
| 4LN2 (Frankfurt) / CAPR (NASDAQ) |
| FRA:4LN2, ETR:4LN2, 4LN2:GR, NASDAQ:CAPR |
| - |
| https://capricor.com/ |
|
Capricor Therapeutics Inc. is a clinical-stage biotechnology company focused on developing transformative cell and exosome-based therapeutics for rare diseases with high unmet medical needs, particularly Duchenne muscular dystrophy (DMD), which cause..
>Volltext.. |
| 1380.87 Mio. EUR |
| 1127.56 Mio. EUR |
| - |
| -91.87 Mio. EUR |
| -90.82 Mio. EUR |
| -1.95 EUR |
| 15.52 Mio. EUR |
| 248.88 Mio. EUR |
| -60.36 Mio. EUR |
| 8.88 |
| -100% |
| -128.79% |
| - |
| - |
| - |
| - |
| CAPRICOR THERAPEUTICS, CAPRICOR THERAPEUTIC |
| 01.04.26 |
|